Full history for every metric is available with a Kvantra account
Nevro Corp. (NVRO)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 390 | 362 | 387 | 406 | 425 | 409 | 409 |
| Operating profit | $m | -126 | -123 | |||||
| Net profit | $m | -104 | -83 | -131 | 3 | -92 | -113 | -113 |
| EPS reported | $ | -3.06 | -3.05 | |||||
| Operating cashflow per share | $ | -0.52 | -0.52 | |||||
| Capex per share | $ | 0.26 | 0.26 | |||||
| FCF per share | $ | -0.79 | -0.79 | |||||
| Free cash flow | $m | -29 | -29 | |||||
| Net debt | $m | -67 | -67 | |||||
| Book value equity | $m | 231 | 231 | |||||
| Book value per share | $ | 6.23 | 6.14 | |||||
| Number of shares | m | 37.09 | 37.62 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.60 | 0.97 | |||||
| P/S LTM | x | 0.34 | 0.55 | |||||
| P/FCF LTM | x | -4.72 | -7.60 | |||||
| EV/EBITDA LTM | x | -2.35 | -2.20 | |||||
| EV/Sales LTM | x | 0.72 | 0.38 | |||||
| Earnings Yield LTM | % | -82.22% | -52.37% | |||||
| FCF Yield | % | -21.18% | -13.16% | |||||
| Quality | ||||||||
| ROE | % | -49.11% | -43.28% | |||||
| ROIC | % | -25.82% | -25.82% | |||||
| Operating margin | % | -30.90% | -30.90% | |||||
| Gross margin | % | 65.98% | 65.98% | |||||
| FCF/Sales | % | -7.15% | -7.15% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -3.92% | -3.92% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.12 | -0.12 | |||||
| Net Debt/EBITDA | x | -1.25 | -1.25 | |||||
| EBIT/Net interest | x | -4.69 | -4.69 | |||||
| Net debt/market cap | % | -48.49% | -29.85% | |||||
| Net debt/Equity | x | -0.29 | -0.29 | |||||
| Gross debt/equity | x | 1.09 | 1.09 | |||||
Company overview
Nevro Corp. is a medical technology firm that delivers solutions for individuals experiencing persistent pain, serving markets both domestically in the United States and across the globe. The company's core business involves the development and market introduction of the Senza spinal cord stimulation (SCS) system, an advanced, clinically supported neuromodulation platform specifically engineered to alleviate chronic pain. This portfolio encompasses its newer generations, the Senza II and Senza Omnia systems. Additionally, Nevro offers its proprietary 10 kHz Therapy, providing neuromodulation approaches grounded in robust clinical evidence for effective chronic pain management. Its products are distributed through a diverse strategy, utilizing a dedicated direct sales team complemented by a network of specialized sales agents and independent distributors. Founded in 2006, Nevro Corp. maintains its corporate headquarters in Redwood City, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Nevro Corp. (NVRO)
Nevro Corp. is a medical technology firm that delivers solutions for individuals experiencing persistent pain, serving markets both domestically in the United States and across the globe. The company's core business involves the development and market introduction of the Senza spinal cord stimulation (SCS) system, an advanced, clinically supported neuromodulation platform specifically engineered to alleviate chronic pain. This portfolio encompasses its newer generations, the Senza II and Senza Omnia systems. Additionally, Nevro offers its proprietary 10 kHz Therapy, providing neuromodulation approaches grounded in robust clinical evidence for effective chronic pain management. Its products are distributed through a diverse strategy, utilizing a dedicated direct sales team complemented by a network of specialized sales agents and independent distributors. Founded in 2006, Nevro Corp. maintains its corporate headquarters in Redwood City, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free